UK Government Drug Price Revamp Move Surprises The ABPI
This article was originally published in Scrip
Executive Summary
Less than two years after the first-ever cap on UK National Health Service drug prices was agreed, the country's Department of Health has announced it wants to change a central part of the pact on grounds it does not provide the NHS with adequate savings or price transparency.
You may also be interested in...
UK Drug Payment Plan To Save £90m Yearly Progresses Through Parliament
Legislation to align NHS statutory pricing scheme with the voluntary PPRS using a payment mechanism based on drug sales raises some industry concerns that it not be used simply as a sales tax. If it proceeds through Parliament as expected, it could take effect by mid-2017.
UK Drug Payment Plan To Save £90m Yearly Progresses Through Parliament
Legislation to align NHS statutory pricing scheme with the voluntary PPRS using a payment mechanism based on drug sales raises some industry concerns that it not be used simply as a sales tax. If it proceeds through Parliament as expected, it could take effect by mid-2017.
Brexit Vote Dismays UK Pharma, Triggers Calls To Leverage NHS As Offset
The UK now urgently needs to leverage the uniqueness of its National Health System to attract global pharma companies and offset the anti-business message contained in Thursday's Brexit vote, and the government's imminent accelerated access review needs to contain the first elements of that objective, according to the Association of the British Pharmaceutical Industry.